Invasive pneumococcal infections in Vellore, India: Clinical characteristics and distribution of serotypes

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Molander, Viktor ^a   Elisson, Camilla ^a   Balaji, Veeraraghavan ^b   Backhaus, Erik ^c   John, James ^b   Vargheese, Rosemol ^b   Jayaraman, Ranjith ^b   Andersson, Rune ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c Research and Development Centre Hospital of Skaraborg   (Sweden)

Author keywords

India; Invasive pneumococcal disease; Pneumococcal vaccine; Pneumococcus; Serotype; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIUM ISOLATE; CLINICAL FEATURE; DISEASE SURVEILLANCE; FATALITY; FEMALE; HUMAN; INDIA; INFANT; INFECTION PREVENTION; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MENINGITIS; NEWBORN; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMONIA; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; CHILD; CLASSIFICATION; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INDIA; INFANT; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84887057143     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-532     Document Type: Article

References (30)

1. Bravo LC. Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 2009, 27:7282-7291. 10.1016/j.vaccine.2009.04.046, 19393708.
2. Sjostrom K, Spindler C, Ortqvist A, Kalin M, Sandgren A, Kuhlmann-Berenzon S, Henriques-Normark B. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42:451-459. 10.1086/499242, 16421787.
3. Brachman PS, Abrutyn E. Bacterial infections of humans: epidemiology and control 2009, New York: Springer Science + Business Media.
4. Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, Ortqvist A, Rello J, Luna CM, Baddour LM, Ip M, Yu VL, Klugman KP. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 2007, 45:46-51. 10.1086/518538, 17554699.
5. Jansen AG, Rodenburg GD, van der Ende A, van Alphen L, Veenhoven RH, Spanjaard L, Sanders EA, Hak E. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009, 49:e23-e29. 10.1086/600045, 19522653.
6. Trollfors B, Berg S, Backhaus E, Andersson R, Bossen Konradsen H. Invasive, paediatric, vaccine strains of Streptococcus pneumoniae: are there differences in clinical characteristics?. Scand J Infect Dis 2009, 41:84-87. 10.1080/00365540802579007, 19012056.
7. Berg S, Trollfors B, Persson E, Backhaus E, Larsson P, Ek E, Claesson BE, Jonsson L, Radberg G, Johansson S, Ripa T, Kaltoft MS, Konradsen HB. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 2006, 38:427-432. 10.1080/00365540500532852, 16798688.
8. Skinner JM, Indrawati L, Cannon J, Blue J, Winters M, Macnair J, Pujar N, Manger W, Zhang Y, Antonello J, Shiver J, Caulfield M, Heinrichs JH. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 2011, 29:8870-8876. 10.1016/j.vaccine.2011.09.078, 21964055.
9. Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013, 30:127-151. 10.1007/s12325-013-0007-6, 23397399.
10. Munoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Infect 2009, 59:75-82. 10.1016/j.jinf.2009.05.012, 19576637.
11. Lalitha MK, Pai R, John TJ, Thomas K, Jesudason MV, Brahmadathan KN, Sridharan G, Steinhoff MC. Serotyping of Streptococcus pneumoniae by agglutination assays: a cost-effective technique for developing countries. Bull World Health Organ 1996, 74:387-390. 2486887, 8823960.
12. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 2006, 44:124-131. 10.1128/JCM.44.1.124-131.2006, 1351965, 16390959.
13. CLSI Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition CLSI document M07-A8. 2009, Wayne, PA: Clinical and Laboratory Standards Institute, CLSI.
14. CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. CLSI document M100-S21. 2011, Wayne, PA: Clinical and Laboratory Standards Institute, CLSI.
15. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902. 10.1016/S0140-6736(09)61204-6, 19748398.
16. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Lancet 1999, 353:1216-1221. 10.1016/S0140-6736(98)07228-6, 10217081, Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India.
17. John TJ, Pai R, Lalitha MK, Jesudason MV, Brahmadathan KN, Sridharan G, Steinhoff MC. Prevalence of pneumococcal serotypes in invasive diseases in southern India. Indian J Med Res 1996, 104:205-207.
18. Jauneikaite E, Jefferies JM, Hibberd ML, Clarke SC. Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine 2012, 30:3503-3514. 10.1016/j.vaccine.2012.03.066, 22475858.
19. Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M, Krogfelt K, Slotved HC, Christensen JJ, Konradsen HB. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010, 50:329-337. 10.1086/649872, 20047478.
20. Henriques Normark B, Kalin M, Ortqvist A, Akerlund T, Liljequist BO, Hedlund J, Svenson SB, Zhou J, Spratt BG, Normark S, Kallenius G. Dynamics of penicillin-susceptible clones in invasive pneumococcal disease. J Infect Dis 2001, 184:861-869. 10.1086/323339, 11550126.
21. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41. 10.1086/648593, 19947881.
22. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768. 10.1016/S1473-3099(11)70090-1, 21621466.
23. Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, Krogfelt KA, Konradsen HB, Benfield TL. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009, 6:e1000081. 10.1371/journal.pmed.1000081, 2680036, 19468297.
24. Yaro S, Lourd M, Traore Y, Njanpop-Lafourcade BM, Sawadogo A, Sangare L, Hien A, Ouedraogo MS, Sanou O, Parent Du Chatelet I, Koeck JL, Gessner BD. Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clin Infect Dis 2006, 43:693-700. 10.1086/506940, 16912941.
25. Leimkugel J, Adams Forgor A, Gagneux S, Pfluger V, Flierl C, Awine E, Naegeli M, Dangy JP, Smith T, Hodgson A, Pluschke G. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis 2005, 192:192-199. 10.1086/431151, 15962213.
26. Antonio M, Hakeem I, Awine T, Secka O, Sankareh K, Nsekpong D, Lahai G, Akisanya A, Egere U, Enwere G, Zaman SM, Hill PC, Corrah T, Cutts F, Greenwood BM, Adegbola RA. Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from The Gambia: expansion of ST217 hypervirulent clonal complex in West Africa. BMC Microbiol 2008, 8:198. 10.1186/1471-2180-8-198, 2587476, 19014613.
27. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, Ki HK, Oh WS, Suh JY, Peck KR, Lee NY, Yang Y, Lu Q, Chongthaleong A, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumarasinghe G, Jamal F, Kamarulzaman A, Parasakthi N, Van PH, Carlos C, So T, Ng TK, Shibl A. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004, 48:2101-2107. 10.1128/AAC.48.6.2101-2107.2004, 415617, 15155207.
28. Levine OS, Cherian T. Pneumococcal vaccination for Indian children. Indian Pediatr 2007, 44:491-496.
29. Lalwani S, Chatterjee S, Chhatwal J, Verghese VP, Mehta S, Shafi F, Borys D, Moreira M, Schuerman L. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study. Human vaccines & immunotherapeutics 2012, 8:612-622. 10.4161/hv.19287, 22634448.
30. Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, Emini EA, Scott DA, Kellner JD. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J 2012, 31:72-77. 10.1097/INF.0b013e318233049d, 21960186.